SEC Comment Letter 0000000000-23-008337 to GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105) (GYRE)
GYRE THERAPEUTICS, INC. (GYRE) (CIK 0001124105)
Date: Aug. 3, 2023 · CIK: 0001124105 · Accession: 0000000000-23-008337
AI Filing Summary & Sentiment
File numbers found in text: 333-273395
Referenced dates: April 27, 2023
Letter
United States securities and exchange commission logo August 3, 2023 Nassim Usman, Ph.D. President and Chief Executive Officer Catalyst Biosciences, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 Re:Catalyst Biosciences, Inc. Registration Statement on Form S-3 Filed July 24, 2023 File No. 333-273395 Dear Nassim Usman: We have limited our review of your registration statement to those issues we have addressed in our comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Registration Statement on Form S-3 filed July 24, 2023 General 1.We note that you plan to acquire an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC, if your stockholders approve the transaction at the special meeting to be held on August 29, 2023. Please revise, as applicable, to provide more specific and prominent disclosures about the legal and operational risks associated with China-based companies. For additional guidance, please see the Division of Corporation Finance’s Sample Letter to China-Based Companies issued by the Staff in December 2021 and Sample Letter to Companies Regarding China-Specific Disclosures issued by the Staff in July 2023. Please also consider the applicable comments issued in our letter dated April 27, 2023, in relation to your Preliminary Proxy Statement on Schedule 14A filed March 30, 2023.
FirstName LastNameNassim Usman, Ph.D. Comapany NameCatalyst Biosciences, Inc. August 3, 2023 Page 2 FirstName LastName Nassim Usman, Ph.D. Catalyst Biosciences, Inc. August 3, 2023 Page 2 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration statement. Please contact Jason Drory at 202-551-8342 or Laura Crotty at 202-551-7614 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Thau
Show Raw Text
United States securities and exchange commission logo
August 3, 2023
Nassim Usman, Ph.D.
President and Chief Executive Officer
Catalyst Biosciences, Inc.
611 Gateway Blvd, Suite 120
South San Francisco, CA 94080
Re:Catalyst Biosciences, Inc.
Registration Statement on Form S-3
Filed July 24, 2023
File No. 333-273395
Dear Nassim Usman:
We have limited our review of your registration statement to those issues we have
addressed in our comment. In our comment, we may ask you to provide us with information so
we may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Registration Statement on Form S-3 filed July 24, 2023
General
1.We note that you plan to acquire an indirect controlling interest in Beijing Continent
Pharmaceuticals Co., Ltd, a company organized under the laws of the PRC, if your
stockholders approve the transaction at the special meeting to be held on August 29, 2023.
Please revise, as applicable, to provide more specific and prominent disclosures about the
legal and operational risks associated with China-based companies. For additional
guidance, please see the Division of Corporation Finance’s Sample Letter to China-Based
Companies issued by the Staff in December 2021 and Sample Letter to Companies
Regarding China-Specific Disclosures issued by the Staff in July 2023. Please also
consider the applicable comments issued in our letter dated April 27, 2023, in relation to
your Preliminary Proxy Statement on Schedule 14A filed March 30, 2023.
FirstName LastNameNassim Usman, Ph.D.
Comapany NameCatalyst Biosciences, Inc.
August 3, 2023 Page 2
FirstName LastName
Nassim Usman, Ph.D.
Catalyst Biosciences, Inc.
August 3, 2023
Page 2
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
statement.
Please contact Jason Drory at 202-551-8342 or Laura Crotty at 202-551-7614 with any
other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephen Thau